CAT and breast cancer: In the 70% field capacity treatment group, catalase (CAT) activity showed a significant decrease when treated with 0.4CMC-BC by 5.02%, and a substantial decrease of 26.40% with 0.4GA3-BC, while 0.8CMC-BC and 0.8GA3-BC treatments resulted in even more substantial reductions of 42.53% and 61.76%, respectively, related to the control.